U.S. CDC recommends use of Novavax’s COVID shot for adolescents
Aug 22 (Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax Inc’s (NVAX.O) COVID-19 vaccine for adolescents aged 12 through 17.
The recommendation follows the U.S. Food and Drug Administration’s authorization for the vaccine for the age group last week.
The protein-based vaccine received emergency use authorization in July for use among adults in the United States, with health officials hoping it would drive uptake among those skeptical of messenger RNA shots from Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N).
U.S. CDC recommends use of Novavax’s COVID shot for adolescents | Reuters